Verastem (NASDAQ:VSTM) released its earnings results on Thursday. The biopharmaceutical company reported ($0.52) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.49) by ($0.03), Morningstar.com reports. The business had revenue of $3.14 million during the quarter, compared to analyst estimates of $2.22 million. Verastem had a negative net margin of 315.21% and a negative return on equity of 79.68%.
Shares of VSTM stock opened at $1.40 on Friday. The stock has a 50 day moving average price of $1.50. The company has a debt-to-equity ratio of 1.42, a current ratio of 7.57 and a quick ratio of 7.56. Verastem has a 12 month low of $1.16 and a 12 month high of $10.35. The company has a market cap of $110.82 million, a P/E ratio of -1.02 and a beta of 2.94.
Hedge funds have recently made changes to their positions in the business. Stratos Wealth Partners LTD. bought a new stake in shares of Verastem in the 1st quarter worth approximately $30,000. Amalgamated Bank bought a new stake in shares of Verastem in the 4th quarter worth approximately $35,000. Principal Financial Group Inc. bought a new stake in shares of Verastem in the 4th quarter worth approximately $35,000. Commonwealth Equity Services LLC lifted its position in shares of Verastem by 43.2% in the 2nd quarter. Commonwealth Equity Services LLC now owns 26,697 shares of the biopharmaceutical company’s stock worth $40,000 after acquiring an additional 8,054 shares during the period. Finally, BNP Paribas Arbitrage SA bought a new stake in shares of Verastem in the 1st quarter worth approximately $42,000. Institutional investors own 43.80% of the company’s stock.
Verastem Company Profile
Verastem, Inc, a biopharmaceutical company, focusing on developing and commercializing medicines to improve the survival and quality of life of cancer patients. It markets COPIKTRA (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K) and dual inhibitor of PI3K-delta and PI3K-gamma, which is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies.
Featured Article: Catch-Up Contributions
Receive News & Ratings for Verastem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verastem and related companies with MarketBeat.com's FREE daily email newsletter.